Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,105 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: calcium Clear all
Completed Phase 1 Interventional Results available

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

NCT02492750
View directory record Official record
Conditions
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Anakinra, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Placebo
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

NCT02020941
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
carfilzomib, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)

NCT00386672
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Reduced energy (lite) OJ fortified with Calcium and Vitamin D, Nutrition Counseling, Reduced energy (lite) OJ without Calcium and Vitamin D
Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

NCT04462523
View directory record Official record
Conditions
Vitreo-Retinal Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Patrick R. Oellers, MD
Network
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional Results available

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

NCT00058188
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
cholecalciferol, calcium gluconate, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer

NCT00003862
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
55
States / cities
Anchorage, Alaska • Phoenix, Arizona • Concord, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Not listed Phase 2 Interventional

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

NCT06321796
View directory record Official record
Conditions
Pitt Hopkins Syndrome
Interventions
MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
5 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Early Phase 1 Interventional

Dilution of Verapamil During Intraarterial Administration

NCT05625503
View directory record Official record
Conditions
Vasospasm;Peripheral, Burning, Pain
Interventions
Verapamil, Nicardipine
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 30, 2026, 4:26 PM EDT
Not yet recruiting Not applicable Interventional

Lifestyle, Education, Activity, Nutrition (LEAN) Into Pregnancy

NCT06879054
View directory record Official record
Conditions
Pregnancy, Preconception Education, Preconception Care, Preconception Risk, Adverse Pregnancy Outcomes
Interventions
Healthy lifestyle education
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT03710772
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Rituximab, Venetoclax, Vincristine Sulfate
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Treatment of Hypovitaminosis D Increase Calcium Absorption?

NCT00581828
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Vitamin D Deficiency, Hypoparathyroidism, Hypercalciuria, Hypercalcemia
Interventions
Vitamin D
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 66 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 4:26 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

NCT00244907
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Genistein vs Risedronate
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 4 Interventional

Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers

NCT01396304
View directory record Official record
Conditions
Venous Ulcer, Infection
Interventions
Restore Calcium Alginate Dressing, AquaCel Ag Wound Dressing
Device
Lead sponsor
Hollister Wound Care LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
St. Petersburg, Florida • Shreveport, Louisiana • Holmdel, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 30, 2026, 4:26 PM EDT
Withdrawn Phase 2 Interventional

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

NCT03168100
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 30, 2026, 4:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692
View directory record Official record
Conditions
Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

NCT00072514
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
gemcitabine hydrochloride, carboplatin, dexamethasone, rituximab
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Recruiting Phase 2 Interventional

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

NCT06855433
View directory record Official record
Conditions
CPPD - Calcium Pyrophosphate Deposition Disease
Interventions
Colchicine Pill, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1 Interventional

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

NCT02293109
View directory record Official record
Conditions
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Mehrdad Abedi, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

NCT00577993
View directory record Official record
Conditions
Lymphoma
Interventions
Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 76 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 30, 2026, 4:26 PM EDT